Gilead Sciences, Inc. on 9 Oct 2020 announced that four abstracts have been selected for poster presentations at the virtual 2020 Asia Pacific AIDS & Co-infections Conference (APACC) being held from October 15-17, 2020. 

The abstracts feature clinical and real-world evidence studies evaluating Gilead’s antiretroviral therapies in HIV including Biktarvy^® (bictegravir/emtricitabine/tenofovir alafenamide) and Genvoya^® (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). Two of the abstracts highlight data from Phase 3 studies evaluating virologically suppressed Asian women and virologically suppressed Asian adults who were randomized either to switch to Biktarvy or stay on their baseline regimen. 

Other abstracts include the latest post-market surveillance data on the use of Genvoya in routine clinical practice in Korea; as well as a study evaluating the persistence of first-line single tablet regimens and multitablet regimens antiretroviral therapy in HIV-1 patients in Japan. 

“The APACC conference is important for continued collaboration and sharing of knowledge with the wider medical and scientific community. We are pleased to be given the opportunity to share our latest clinical data specific to Asians living with HIV at the upcoming forum,” said Dr Kuan-Yeh Lee, Director of HIV Medical Affairs, Asia, Gilead Sciences.  

Details for all accepted abstracts are as follows: